Urothelial glycosaminoglycan layer (GAG layer)

The urothelial glycosaminoglycan (GAG) layer is a specialized, hydrophilic coating of polysaccharides located on the luminal surface of the bladder's umbrella cells [1, 6]. It is primarily composed of molecules such as hyaluronic acid, chondroitin sulfate, heparan sulfate, and dermatan sulfate, which collectively form a highly impermeable barrier [1, 10]. This layer serves a critical physiological role by preventing the adherence of uropathogens and shielding the underlying urothelium from irritating urinary solutes, including potassium ions, urea, and various toxins [2, 5]. When the GAG layer is damaged or deficient, these irritants can penetrate the bladder wall, triggering neurogenic inflammation, mast cell activation, and chronic pain [5, 8]. In clinical practice, the GAG layer is a primary therapeutic target for conditions like interstitial cystitis/bladder pain syndrome (IC/BPS), recurrent urinary tract infections, and radiation-induced cystitis [1, 7]. Treatments known as GAG replenishment therapies aim to restore the integrity of this barrier using exogenous agents [7, 11]. These include oral medications like pentosan polysulfate sodium and intravesical instillations of hyaluronic acid, chondroitin sulfate, or heparin [5, 10]. By reconstituting the protective mucus layer, these therapies help to reduce bladder permeability, alleviate symptoms of urgency and frequency, and promote the healing of the urothelial surface [3, 12].

Other names

Bladder glycosaminoglycan layerUrothelial mucin layerBladder surface glycosaminoglycansUrothelial glycocalyx

Replenishment of the protective barrier to restore urothelial impermeability and reduce neurogenic inflammation.